Generali Investments CEE investicni spolecnost a.s. Buys Shares of 2,900 Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Generali Investments CEE investicni spolecnost a.s. purchased a new stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) during the fourth quarter, according to its most recent filing with the SEC. The firm purchased 2,900 shares of the biopharmaceutical company’s stock, valued at approximately $682,000.

Several other large investors have also recently made changes to their positions in the stock. Raymond James Financial Inc. purchased a new position in Alnylam Pharmaceuticals in the fourth quarter worth $65,295,000. Jennison Associates LLC purchased a new position in Alnylam Pharmaceuticals during the 4th quarter worth $61,160,000. Proficio Capital Partners LLC increased its position in Alnylam Pharmaceuticals by 25,929.6% during the 4th quarter. Proficio Capital Partners LLC now owns 193,660 shares of the biopharmaceutical company’s stock valued at $45,570,000 after buying an additional 192,916 shares in the last quarter. Strategic Financial Concepts LLC purchased a new stake in Alnylam Pharmaceuticals in the fourth quarter valued at about $41,529,000. Finally, Eventide Asset Management LLC boosted its holdings in Alnylam Pharmaceuticals by 157.9% in the third quarter. Eventide Asset Management LLC now owns 224,333 shares of the biopharmaceutical company’s stock worth $61,698,000 after acquiring an additional 137,333 shares in the last quarter. 92.97% of the stock is owned by institutional investors.

Insider Buying and Selling

In related news, CMO Pushkal Garg sold 52,592 shares of the company’s stock in a transaction dated Monday, January 27th. The shares were sold at an average price of $285.00, for a total transaction of $14,988,720.00. Following the completion of the sale, the chief marketing officer now owns 11,989 shares of the company’s stock, valued at approximately $3,416,865. This represents a 81.44 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Phillip A. Sharp sold 11,250 shares of the firm’s stock in a transaction that occurred on Thursday, January 23rd. The stock was sold at an average price of $275.00, for a total transaction of $3,093,750.00. The disclosure for this sale can be found here. In the last three months, insiders have sold 72,986 shares of company stock worth $20,397,849. Insiders own 1.50% of the company’s stock.

Analysts Set New Price Targets

Several brokerages recently commented on ALNY. Canaccord Genuity Group increased their price objective on shares of Alnylam Pharmaceuticals from $384.00 to $385.00 and gave the company a “buy” rating in a research report on Tuesday, February 18th. William Blair reissued an “outperform” rating on shares of Alnylam Pharmaceuticals in a report on Wednesday, February 26th. Sanford C. Bernstein cut their target price on Alnylam Pharmaceuticals from $314.00 to $310.00 and set an “outperform” rating on the stock in a research report on Tuesday, January 7th. Needham & Company LLC reiterated a “buy” rating and set a $320.00 price target on shares of Alnylam Pharmaceuticals in a research note on Wednesday, February 26th. Finally, Chardan Capital restated a “buy” rating and issued a $300.00 price objective on shares of Alnylam Pharmaceuticals in a research note on Wednesday, February 26th. One equities research analyst has rated the stock with a sell rating, six have issued a hold rating and nineteen have issued a buy rating to the company. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $304.26.

Alnylam Pharmaceuticals Stock Performance

Shares of ALNY stock opened at $244.52 on Friday. The company has a market capitalization of $31.65 billion, a P/E ratio of -112.68 and a beta of 0.39. Alnylam Pharmaceuticals, Inc. has a 12-month low of $141.98 and a 12-month high of $304.39. The business’s 50 day moving average is $254.70 and its two-hundred day moving average is $261.37. The company has a current ratio of 2.78, a quick ratio of 2.71 and a debt-to-equity ratio of 15.27.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last released its quarterly earnings results on Thursday, February 13th. The biopharmaceutical company reported ($0.65) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.62) by ($0.03). Analysts expect that Alnylam Pharmaceuticals, Inc. will post -1.7 EPS for the current fiscal year.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.